Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
16 April, 2024 19:27 IST
Angel Broking maintains 'Buy' on Ipca Laboratories
Source: IRIS | 22 Sep, 2014, 04.17PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

Health Canada has asked Ipca Laboratories, to voluntarily stop shipment of products to Canada on account of on a review of recent GMP inspection report by US FDA where they identified falsification and manipulation of data issues. Ipca has not disputed the FDA findings with Health Canada. However, the FDA has not issued a recall of any of the affected products. Health Canada estimates that this affects approximately 21 active pharmaceutical ingredients (APIs).
 
Commenting on the same, Sarabjit Kour Nangra, VP Research, IT, Angel Broking, said, ''The department has also asked Canadian companies that import product containing APIs from the Ipca facilities to temporarily quarantine these products. To date, there has been no indication that the issues identified during the FDA inspection pose a risk to health. Therefore, like the FDA, Health Canada is not requesting a recall of products already on the market. If the situation changes, the Department will take immediate action and inform Canadians.
 
As part of a normal process, regulators around the world share information and inspection reports. Health Canada continues to work with other international regulatory partners, Canadian importers and Ipca to gather more information about the products involved. The information being sought includes any additional testing being done, the medical necessity of the products involved, their market share, and risk assessments.
 
In terms of numbers, the recall will not have major impact on the financials of the company. We maintain our buy with a target of Rs 986.''

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.

 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer